JP2021505663A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021505663A5 JP2021505663A5 JP2020548894A JP2020548894A JP2021505663A5 JP 2021505663 A5 JP2021505663 A5 JP 2021505663A5 JP 2020548894 A JP2020548894 A JP 2020548894A JP 2020548894 A JP2020548894 A JP 2020548894A JP 2021505663 A5 JP2021505663 A5 JP 2021505663A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- cancer
- dclk1
- antibody
- car
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023151660A JP2023165793A (ja) | 2017-12-04 | 2023-09-19 | 抗ｄｃｌｋ１抗体およびキメラ抗原受容体、ならびにこれらの組成物および使用方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762594464P | 2017-12-04 | 2017-12-04 | |
| US62/594,464 | 2017-12-04 | ||
| PCT/US2018/063702 WO2019112978A2 (en) | 2017-12-04 | 2018-12-03 | Anti-dclk1 antibodies and chimeric antigen receptors, and compositions and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023151660A Division JP2023165793A (ja) | 2017-12-04 | 2023-09-19 | 抗ｄｃｌｋ１抗体およびキメラ抗原受容体、ならびにこれらの組成物および使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021505663A JP2021505663A (ja) | 2021-02-18 |
| JP2021505663A5 true JP2021505663A5 (https=) | 2022-01-11 |
| JP7409669B2 JP7409669B2 (ja) | 2024-01-09 |
Family
ID=66751211
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020548894A Active JP7409669B2 (ja) | 2017-12-04 | 2018-12-03 | 抗ｄｃｌｋ１抗体およびキメラ抗原受容体、ならびにこれらの組成物および使用方法 |
| JP2023151660A Pending JP2023165793A (ja) | 2017-12-04 | 2023-09-19 | 抗ｄｃｌｋ１抗体およびキメラ抗原受容体、ならびにこれらの組成物および使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023151660A Pending JP2023165793A (ja) | 2017-12-04 | 2023-09-19 | 抗ｄｃｌｋ１抗体およびキメラ抗原受容体、ならびにこれらの組成物および使用方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US12084514B2 (https=) |
| EP (1) | EP3720481A4 (https=) |
| JP (2) | JP7409669B2 (https=) |
| CN (1) | CN111818939B (https=) |
| CA (1) | CA3122010A1 (https=) |
| WO (1) | WO2019112978A2 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11274144B2 (en) | 2013-06-13 | 2022-03-15 | Research Institute At Nationwide Children's Hospital | Compositions and methods for the removal of biofilms |
| WO2017023863A1 (en) | 2015-07-31 | 2017-02-09 | Research Institute At Nationwide Children's Hospital | Peptides and antibodies for the removal of biofilms |
| EP3630046B1 (en) * | 2017-05-30 | 2024-12-25 | The Board of Regents of the University of Oklahoma | Anti-doublecortin-like kinase 1 antibodies and methods of use |
| US12084514B2 (en) | 2017-12-04 | 2024-09-10 | The Board Of Regents Of The University Of Oklahoma | Anti-DCLK1 antibodies and chimeric antigen receptors, and compositions and methods of use thereof |
| AU2020311897A1 (en) | 2019-07-08 | 2022-02-03 | Research Institute At Nationwide Children's Hospital | Antibody compositions for disrupting biofilms |
| WO2021046331A1 (en) * | 2019-09-05 | 2021-03-11 | Memorial Sloan Kettering Cancer Center | Anti-steap1 antibodies and uses thereof |
| WO2024118940A1 (en) * | 2022-12-01 | 2024-06-06 | Twist Bioscience Corporation | Anti-psma antibodies and uses thereof |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2631327C (en) | 2005-12-02 | 2015-10-13 | Genentech, Inc. | Her2 binding polypeptides and uses thereof |
| WO2008030543A2 (en) * | 2006-09-08 | 2008-03-13 | Cell Signaling Technology, Inc. | Tyrosine, serine and threonine phosphorylation sites |
| US8936941B2 (en) | 2008-04-03 | 2015-01-20 | The Board Of Regents Of The University Of Oklahoma | Compositions useful for cancer detection and treatment, a cancer stem cell model, and methods of production and use thereof |
| US7902166B2 (en) | 2008-04-03 | 2011-03-08 | The Board Of Regents Of The University Of Oklahoma | Compositions comprising inhibitors of RNA binding proteins and methods of producing and using same |
| US9663585B2 (en) * | 2008-05-16 | 2017-05-30 | The Board Of Regents Of The University Of Oklahoma | Anti-DCLK1 monoclonal antibodies and methods of production and use thereof |
| PH12013501201A1 (en) * | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| BR112014024023A2 (pt) | 2012-03-28 | 2017-07-18 | Genentech Inc | anticorpos idiotípicos anti-hcmv e usos dos mesmos |
| CN105792836A (zh) | 2013-08-28 | 2016-07-20 | 施特姆森特克斯股份有限公司 | 新型sez6调节剂以及应用方法 |
| GB2537445A (en) * | 2014-11-10 | 2016-10-19 | Medimmune Ltd | Binding molecules specific for CD73 and uses thereof |
| CN107750255B (zh) * | 2015-04-17 | 2022-08-30 | 安进研发（慕尼黑）股份有限公司 | 用于cdh3和cd3的双特异性抗体构建体 |
| US9822184B2 (en) | 2015-04-22 | 2017-11-21 | The Board Of Regents Of The University Of Texas System | DCLK1 short form specific binding agents |
| EP3630046B1 (en) | 2017-05-30 | 2024-12-25 | The Board of Regents of the University of Oklahoma | Anti-doublecortin-like kinase 1 antibodies and methods of use |
| US12084514B2 (en) * | 2017-12-04 | 2024-09-10 | The Board Of Regents Of The University Of Oklahoma | Anti-DCLK1 antibodies and chimeric antigen receptors, and compositions and methods of use thereof |
-
2018
- 2018-12-03 US US16/769,567 patent/US12084514B2/en active Active
- 2018-12-03 JP JP2020548894A patent/JP7409669B2/ja active Active
- 2018-12-03 CN CN201880087617.8A patent/CN111818939B/zh active Active
- 2018-12-03 CA CA3122010A patent/CA3122010A1/en active Pending
- 2018-12-03 EP EP18885373.3A patent/EP3720481A4/en active Pending
- 2018-12-03 WO PCT/US2018/063702 patent/WO2019112978A2/en not_active Ceased
-
2023
- 2023-09-19 JP JP2023151660A patent/JP2023165793A/ja active Pending
-
2024
- 2024-01-30 US US18/427,038 patent/US12415867B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021505663A5 (https=) | ||
| JP7061235B2 (ja) | 抗ｃｌｄ１８ａ２ナノ抗体及びその応用 | |
| US11382963B2 (en) | Engineered T cells and uses therefor | |
| JP7573441B2 (ja) | ガイダンス及びナビゲーションコントロール蛋白質並びにその生産及び使用方法 | |
| JP7222600B2 (ja) | 腫瘍細胞に特異的なキメラ抗原レセプター | |
| CN109734813B (zh) | 一种嵌合抗原受体及其应用 | |
| CN109651511B (zh) | 一种靶向bcma的嵌合抗原受体及其应用 | |
| JP2023082052A (ja) | キメラ抗原受容体およびその使用 | |
| CN110214152B (zh) | 模块化四聚体双特异性抗体平台 | |
| JP2022500419A (ja) | 腫瘍を治療するためのナチュラルキラー細胞組成物および免疫療法の方法 | |
| AU2017384900A1 (en) | Chimeric antigen receptor and natural killer cells expressing same | |
| JP2018529380A5 (https=) | ||
| CN110035768A (zh) | 嵌合抗原受体 | |
| KR102316091B1 (ko) | Bcma를 표적으로 하는 키메라 항원 수용체 및 이의 용도 | |
| JP2020501512A5 (https=) | ||
| JP2018513687A5 (https=) | ||
| WO2018132513A1 (en) | T cells experessing a chimeric antigen receptor | |
| JP2018518151A5 (https=) | ||
| JP2024501888A (ja) | Ｂｃｍａに特異的に結合する抗体およびその使用 | |
| KR20210143096A (ko) | Cd22에 특이적인 항체 및 이의 용도 | |
| US12251447B2 (en) | Combined formulation comprising four linked cytotoxic T lymphocyte (CTL) epitopes and a PD-1 pathway inhibitor and methods of use thereof to treat cancer | |
| KR20220122844A (ko) | Cd22에 특이적인 인간화 항체 및 이의 용도 | |
| US20240342281A1 (en) | Use of a stromal antigen to deliver cell-based cancer therapy to a solid tumor | |
| JP7619682B2 (ja) | Ｃｄ２２に特異的なヒト化抗体およびそれを用いたキメラ抗原受容体 | |
| CN113549155A (zh) | 同时靶向cd19和cd20的嵌合抗原受体及其应用 |